Scholars Central

Research articlePublished 16 Feb 2017

Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes

Authors: J. Zekri, A. Al-Shehri, M. Mahrous, S. Al-Rehaily, T. Darwish, S. Bassi, H. El Taani, A. Al Zahrani, S. Elsamany, J. Al-Maghrabi, B.B. Sadiq

Genetics and Molecular Research

Volume 16 · Issue 1 · Pages 1–11

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Mutations in codons 12/13 of K-ras exon 2 are associated with reduced benefit from anti-epidermal growth factor receptor antibody treatment for metastatic colorectal cancer (CRC). Here, we evaluated the frequency of K-ras mutations and their relationship with clinicopathological features and treatment outcomes in Saudi Arabian patients with CRC. The genetic status of K-ras was determined in 300 patients diagnosed with CRC. Clinical information was collected retrospectively. K-ras was wild-type in 58% and mutated in 42% of the tumors. Most mutations were at codon 12 (89%) and were associated with metastasis [odds ratio (OR) = 1.38 (95%CI = 1.14-1.67] and occurrence of >40 µg/L carcinoembryonic antigen (CEA) [OR = 1.33 (1.1-1.74)] during diagnosis. Patients in stages I-III of the disease with wild-type K-ras tumors had a median relapse free survival (RFS) of 29 months in contrast to 22 months for those with the mutated K-ras tumor (P = 0.0357). In multivariate analysis, only the stage of the disease significantly predicted RFS (P = 0.001). Patients in stage IV of CRC with the wild-type K-ras tumor did not reach the median overall survival (OS), whereas patients with the mutated K-ras tumor survived for 23.5 months (P = 0.044). CEA level >40 µg/L (P = 0.004) and status of K-ras (P = 0.044) were independent predictors of OS. This is the largest study investigating K-ras mutations in patients with CRC in the Middle East. Mutations were associated with advanced stage of CRC, higher serum CEA, shorter RFS and OS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Genetics and Molecular Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalGenetics and Molecular Research
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “J. Zekri”
  • BylineArticles whose byline prints “A. Al-Shehri”
  • BylineArticles whose byline prints “M. Mahrous”
  • BylineArticles whose byline prints “S. Al-Rehaily”
  • BylineArticles whose byline prints “T. Darwish”
  • BylineArticles whose byline prints “S. Bassi”
  • BylineArticles whose byline prints “H. El Taani”
  • BylineArticles whose byline prints “A. Al Zahrani”